Addiction Is a Brain Disease — and What That Means in 2026

When the National Institute on Drug Abuse published its first comprehensive statement of the brain-disease model in the 1990s, the field was contending with a stigma framework that treated addiction as moral weakness. The reframe — addiction is a chronic, relapsing brain disorder — was a clinical and political revolution.

Thirty years on, the model remains essentially correct. It also turns out to be more complicated than its original articulation suggested.

What the brain-disease model gets right

Repeated substance use produces measurable, lasting changes in the brain’s reward, executive-control, and stress systems. These changes are not metaphorical. Neuroimaging across substance classes consistently shows altered dopamine signaling, prefrontal cortex hypofunction, and amygdala hyperactivity that persist long after acute use.

These are the substrate of cravings, of impaired decision-making in moments of stress, and of relapse triggers. They are also why the brain-disease framing predicts treatment response: like other chronic diseases, addiction responds best to long-term medication plus behavioral support, not to acute interventions.

What’s been refined

• The disease isn’t only neurobiological. Social determinants — poverty, trauma, isolation — predict initiation and recovery as powerfully as any neurochemical variable.
• Recovery is not symptom-free abstinence. It is functional restoration, which can include MAT, harm reduction, and continued substance use under managed conditions.
• Genetic risk is real but overstated. Heritability estimates of 40–60% mean environment is the larger lever for most populations.

Why the framework still matters

Without the brain-disease model, the United States does not have buprenorphine, the parity laws that make it billable, or the Medicaid coverage that makes it accessible. The model is not perfect. It is the foundation of every evidence-based intervention currently available.

— Further reading: NIDA Research, Volkow et al., NEJM 2016.